Iconovo’s ICOone® inhaler platform receives new patent approval in the US
The United States Patent and Trademark Office (USPTO) intends to approve an additional patent for ICOone®, Iconovo’s nnovative inhaler platform that enables convenient and cost-effective administration of vaccines and biologics. Iconovo is already pursuing several development projects based on ICOone®, including one with financial support from the Bill & Melinda Gates Foundation.
ICOone® is Iconovo’s inhaler platform for convenient and cost-effective administration of vaccines and biologics. Since ICOone® can be loaded with the active ingredient in the form of a dry powder, expensive and complicated cold storage is not required. In addition, it avoids the handling of disposable syringes and used needles that can spread blood-borne infections. Today’s announcement from the USPTO means that ICOone® will be protected by two patents in the US market. The inhaler also has patent protection inthe rest of Europe (EPO), India, China, and Japan.
Read the full press release here